Adults with cystic fibrosis experience higher pain prevalence and severity compared to healthy controls, with significant unmet needs in pain management. New study highlights critical gaps in care.

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

Young Minuteman Press franchise owner, Caroline Sweeney, has brought fresh energy and new potential to her Ashland based ...

Robert F. Kennedy Jr., Trump’s pick for health secretary, sought to use Samoa’s measles vaccine pause as a "natural ...

STEM Potential supports you through years 10 and 12 with insightful lectures, subject-specific workshops and a non-residential summer school. STEM Potential is a multi-year programme of activities and ...

The city of Savannah could receive $146 million in grants and favorable loans for improvements at its Industrial & Domestic Water Treatment Plant. The funding would be from a potential $502 ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis ... candidate with the potential to ...

Cystic fibrosis is a rare, life-shortening disease that affects over 90,000 people worldwide. It is caused by mutations in the CFTR ion channel, resulting in the aberrant flow of salt and water in ...

Dana Schulz is an experienced editor, writer, and content strategist who is just as likely to be crunching the ...